Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2022

Genmab — Oktober 2022

Planlagt Fastgjort Låst Flyttet Genmab
641 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #110

    Godmorgen. 🙂

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Riis7
      wrote on sidst redigeret af
      #111

      Godmorgen:-)

      1 Reply Last reply
      0
      • SvingtraderenS Offline
        SvingtraderenS Offline
        Svingtraderen
        wrote on sidst redigeret af
        #112

        Genmab kan have en værdig afløser til supersællerten Darzalex på vej, vurderer Handelsbanken, der dog også ser risici forbundet med potentielt nye krav i USA til udviklingen af kræftmidler.

        Handelsbanken har netop været vært for et arrangement med Genmabs IR-team, og her blev der fokuseret på Genmabs mulige afløser til Darzalex, Hexabody-CD38.

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #113

          Just a moment...

          favicon

          (www.proinvestor.com)

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #114

            Det bedste ville være en værdig afløser (specielt hvis voldgiften tabes) - det næstbedste er muligheder i andre indikationer.

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #115

              Endnu bedre hvis begge dele. Vi får nok en ide om det på ASH, idet eskalations-data og RP2D i MM forlængst er klar.

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #116

                Muligvis er de nået så langt i expansions-fasen, at vi også kan få lidt nyt her på ASH.

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #117

                  Winkel på sidste CC: HexaBody-CD38, we are very excited about the data. You will see the dose escalation data this year

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #118

                    Mht Handelsbankens bekymringer om FDA's projekt optimus vedr krav til doseringer i forsøg, så er Genmab måske det bedst rustede af alle biotek til lidt forhøjede omkostninger kva deres enorme kontantbeholdning.

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #119

                      Projekt Optimus https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #120

                        Har lavet et spm til Winkel vedr Optimus til næste Q&A.

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #121

                          Det har Winkel selv nævnt et par gange under de seneste CC´s - og tror allerede de er i gang med Epcoritamab

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #122

                            Winkel på Q1 CC: the other program, which I've spoken about at the full year results in February, the Optimus program, which is requiring more dosing iterations, which is certainly going to be asked from Genmab as well as from all other companies in the oncology area and the rationale that perhaps in some combinations, one could use a lower dose of the therapeutic candidates than what is used in monotherapy, Asthika.

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #123

                              And that could, of course, slow down a bit the development unless you agree with the regulator to do multiple arm studies. And again, Genmab is now in a position with a better pipeline than we ever had before, a better team that we ever had before in our history and a robust cash position to do actually multiple arm studies also under the Optimus program to actually very quickly titrate and get optimal doses of new therapeutic antibody candidates. So yeah, we are very busy.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #124

                                Det gode er trods alt, at det jo også gælder for konkurrenterne - og i sidste ende kan det jo betyde bedre lægemidler

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #125

                                  Kandidater der er langt fremme i udvikling kunne man nok tænke sig slap med et par fase 4 forsøg.

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #126

                                    Hvis Optimus bevirker en forsinkelse og fordyrelse af studierne, så vil omvendt Frontrunner programmet kunne føre til hurtigere adgang til 1. linje, hvor det store salg ligger.

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #127

                                      USA: Beskæftigelsen voksede mere end ventet i september https://www.proinvestor.com/investornyt/887710/usa-beskaeftigelsen-voksede-mere-end-ventet-i-september-ny

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #128

                                        Renter stiger og aktier falder efter jobtal https://www.proinvestor.com/investornyt/887711/renter-stiger-og-aktier-falder-efter-jobtal-ny

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #129

                                          MajesTEC-9- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT05572515

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper